NAT2 and tuberculosis: Individuals with NAT2 slow acetylator genotypes (homozygotes or compound heterozygotes for NAT2*5, *6, or *7) are associated with an increased risk of anti-tuberculosis drug-induced liver injury [51], risk of cotrimoxazole adverse events in patients with systemic lupus erythematosus [52], and risk of sulfasalazine-induced toxicity [53].